Recent Material Events

Track the latest material events (8-K filings) with AI-powered analysis. Stay informed about major corporate developments, acquisitions, and changes.

📊 1024 Events

🤖 AI Analyzed

Recent

📄 Page 66 of 86

Arbutus Biopharma Corp

8-K March 3, 2026

Key Highlights

Settled patent infringement lawsuit with Moderna, resolving a major legal disput...
Secured a guaranteed $950 million cash payment from Moderna.
Potential for up to an additional $1.3 billion contingent payment based on Moder...

Read Analysis

🤖 AI Generated

PDS Biotechnology Corp

8-K March 3, 2026

Key Highlights

Positive Phase 2 clinical trial results for PDS0101 in HPV16-positive head and n...
PDS0101 showed significant promise with improved overall response rate (ORR), co...
Clinical success suggests a significant market opportunity and moves the company...

Read Analysis

🤖 AI Generated

Karyopharm Therapeutics Inc.

8-K March 3, 2026

Key Highlights

Conditional lifeline provides temporary reprieve and delays debt payments.
Opportunity to focus on crucial Phase 3 XPOVIO trial for endometrial cancer.
Successful capital raise and positive trial results could stabilize the company.

Read Analysis

🤖 AI Generated

LINDBLAD EXPEDITIONS HOLDINGS, INC.

8-K March 3, 2026

Key Highlights

Lindblad increased its ownership in Natural Habitat to 95%, enhancing control an...
The acquisition reinforces Lindblad's strategy in the high-growth experiential t...
Natural Habitat has historically been a strong contributor to Lindblad's revenue...

Read Analysis

🤖 AI Generated

Arq, Inc.

8-K March 3, 2026

Key Highlights

Temporary operational flexibility gained by reducing the minimum cash requiremen...
Potential for increased access to capital through modifications to the borrowing...
Lenders (MidCap Funding IV Trust) are actively working with Arq, demonstrating a...

Read Analysis

🤖 AI Generated

Quipt Home Medical Corp.

8-K March 3, 2026

Key Highlights

Shareholders overwhelmingly approved the acquisition, paving the way for privati...
Shareholders will receive US$3.65 in cash per share, offering immediate and cert...
The Board of Directors unanimously recommended the deal, believing it serves sha...

Read Analysis

🤖 AI Generated

Synergy CHC Corp.

8-K March 3, 2026

Key Highlights

Synergy CHC Corp. (SNYR) faces a significant setback with the termination of a k...
The agreement, covering FOCUSfactor and Flat Tummy Co. products in UAE and Turke...
Synergy intends to continue pursuing registration and marketing of its products ...

Read Analysis

🤖 AI Generated

Theravance Biopharma, Inc.

8-K March 3, 2026

Key Highlights

Targeted 60% reduction in annual operating expenses, equating to $70 million in ...
Shift to a leaner, commercially focused entity, prioritizing existing assets (YU...
Aim to improve financial stability and extend cash runway, potentially moving to...

Read Analysis

🤖 AI Generated

Hepion Pharmaceuticals, Inc.

8-K March 3, 2026

Key Highlights

Strategic diversification into liver health diagnostics, complementing existing ...
Acquisition of a novel diagnostic tool for early detection of hepatocellular car...
Potential to significantly improve patient outcomes for severe liver cancer by e...

Read Analysis

🤖 AI Generated

CAL-MAINE FOODS INC

8-K March 3, 2026

Key Highlights

Strategic acquisition of Creighton Brothers' egg businesses for approximately $1...
Significantly expands market reach, adds 6.5 million laying hens, and diversifie...
Funded entirely by existing cash reserves, expected to immediately boost EPS, re...

Read Analysis

🤖 AI Generated

Roivant Sciences Ltd.

8-K March 3, 2026

Key Highlights

Secured $950 million guaranteed payment from Moderna patent settlement.
Potential for an additional $1.3 billion from ongoing legal appeal.
Expanded share repurchase program to $1.0 billion, signaling strong shareholder ...

Read Analysis

🤖 AI Generated

Iterum Therapeutics plc

8-K March 3, 2026

Key Highlights

Nasdaq notified Iterum Therapeutics of intent to delist its stock on February 24...
The company is exploring strategic options including a potential wind-down of op...
Shareholders face a significant risk of losing their entire investment.

Read Analysis

🤖 AI Generated

Stay Informed with AI Analysis

Get comprehensive insights from material event filings with our AI-powered analysis. Track corporate developments, acquisitions, and strategic changes.

Back to Homepage